Show simple item record

dc.contributor.authorDepartment of Health (DoH)
dc.date.accessioned2012-11-09T12:03:53Z
dc.date.available2012-11-09T12:03:53Z
dc.date.issued1988-11
dc.identifier.urihttp://hdl.handle.net/10147/251585
dc.descriptionBacillus Calmette-Guerin (BCG) vaccine has been used in the fight against tuberculosis Since the 1920's. Although some trial results have seriously questioned its efficacy and effectiveness, BCG has continued to be used extensively in many countries as a preventive vaccine against tuberculosis. In more recent times. the wisdom of routinely vaccinating all infants shortly after birth has been called into question. One of the disadvantages of BCG in the loss of the tuberculin test as an indicator of natural infection with tubercle bacilli. and consequently BCG vaccination may interfere with population surveillance as regards tuberculosis Infection. A group of specialists in Community Medicine formed a committee to examine the present situation in Ireland as regards tuberculosis and the need for routine infant BCG vaccination.en_GB
dc.language.isoenen
dc.publisherDepartment of Health (DoH)en_GB
dc.subjectVACCINESen_GB
dc.subjectTUBERCULOSISen_GB
dc.titlePolicy on BCG vaccination: a reviewen_GB
dc.typeReporten
refterms.dateFOA2018-08-23T02:14:36Z


Files in this item

Thumbnail
Name:
PolicyOnBCGvaccinationAReview.pdf
Size:
4.585Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record